Trial Profile

Prospective Clinical Study to Observe the Efficacy and Safety of Iguratimod in Rheumatoid Arthritis and Early Rheumatoid Arthritis Patients for 6 Months Treatment in China

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 22 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Nov 2023 Status changed from active, no longer recruiting to completed.
03 Jun 2023 Results (n=246) assessing the long-term efficacy, safety, and recurrence of Iguratimod combination with csDMARDs in the treatment of active rheumatoid arthritis and the characteristic of patients who obtain the most benefit from Iguratimod, presented at the 24th Annual Congress of the European League Against Rheumatism.
18 Sep 2022 Planned End Date changed from 11 Dec 2021 to 31 Dec 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com